Franklin Resources Inc. Has $2.77 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Franklin Resources Inc. boosted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 52.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,101 shares of the company's stock after buying an additional 42,315 shares during the period. Franklin Resources Inc. owned about 0.17% of Nurix Therapeutics worth $2,766,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Driehaus Capital Management LLC acquired a new position in shares of Nurix Therapeutics in the 2nd quarter valued at about $26,778,000. Samlyn Capital LLC acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at $12,177,000. Sumitomo Mitsui Trust Group Inc. purchased a new position in shares of Nurix Therapeutics during the 3rd quarter valued at $12,432,000. FMR LLC raised its holdings in shares of Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company's stock worth $13,188,000 after acquiring an additional 511,256 shares in the last quarter. Finally, Patient Square Capital LP acquired a new stake in Nurix Therapeutics during the third quarter valued at $7,320,000.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on NRIX shares. Oppenheimer lifted their price target on Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a report on Wednesday, September 4th. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. Robert W. Baird started coverage on shares of Nurix Therapeutics in a research note on Friday, September 6th. They set an "outperform" rating and a $26.00 price target on the stock. Royal Bank of Canada reduced their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. Finally, Stephens reissued an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a research report on Monday, October 14th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $30.35.

Nurix Therapeutics Stock Up 1.8 %

Nurix Therapeutics stock traded up $0.36 during mid-day trading on Thursday, reaching $19.93. The company had a trading volume of 454,897 shares, compared to its average volume of 905,871. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -6.85 and a beta of 2.12. The company has a 50 day moving average of $23.03 and a 200-day moving average of $22.39. Nurix Therapeutics, Inc. has a 52 week low of $7.65 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). The business had revenue of $12.59 million during the quarter, compared to analysts' expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. On average, analysts predict that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In related news, insider Christine Ring sold 3,290 shares of the business's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the sale, the insider now owns 24,592 shares of the company's stock, valued at $614,800. The trade was a 11.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,368 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares of the company's stock, valued at $905,661. This represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,401 shares of company stock valued at $437,453. 9.80% of the stock is owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.